Search results for "228"

showing 4 items of 834 documents

The Apnea-Hypopnea Index Underestimates Systemic Inflammation in Women with Sleep-Disordered Breathing.

2018

Evidence suggests that sleep-related respiratory and related metabolic compromise may vary between females and males with sleep-disordered breathing (SDB). Our purpose was to elucidate possible gender differences in sleep-associated respiratory and inflammatory parameters in patients with SDB.A consecutive number of SDB patients (46 females and 167 males) who underwent polysomnography were retrospectively reviewed. Fibrinogen and C-reactive protein (CRP) concentration, apnea index (ApnI), hypopnea index (HypI), apnea-hypopnea index (AHI), average and minimal SpOApnI and AHI were significantly higher in males. Correlation analysis revealed striking gender differences: only in females, CRP co…

AdultMalemedicine.medical_specialtyPolysomnographyPolysomnography030204 cardiovascular system & hematologyBody Mass Index03 medical and health sciences0302 clinical medicineSleep Apnea SyndromesRisk FactorsInternal medicinemedicineHumansObesityAgedRetrospective StudiesInflammationSleep Apnea Obstructivebiologymedicine.diagnostic_testbusiness.industryC-reactive proteinSnoringApneaFibrinogenGeneral MedicineMiddle Agedmedicine.diseasenervous system diseasesrespiratory tract diseasesObstructive sleep apneaC-Reactive Protein030228 respiratory systemApnea–hypopnea indexCardiologyBreathingbiology.proteinFemalemedicine.symptombusinessHypopneaBody mass indexJournal of women's health (2002)
researchProduct

The Importance of Phenotyping Bronchiectasis.

2016

Bronchiectasis is considered to be one of the most heterogeneous respiratory diseases due to both multiple etiological conditions and variable clinical manifestations. This huge heterogeneity is one of the main reasons for disease complexity, and thus, there is a need to identify clinical phenotypes which have specific therapeutic and follow-up indications as in other respiratory diseases [i.e. chronic obstructive pulmonary disease (COPD) or asthma]. Unfortunately, identifying phenotypes of bronchiectasis is not an easy task, and so far, attempts to link aetiology to clinical severity have failed.

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyBronchiectasisbusiness.industrySettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseaseBronchiectasis03 medical and health sciences0302 clinical medicine030228 respiratory systemmedicineHumans030212 general & internal medicinebusinessRespiration; international review of thoracic diseases
researchProduct

Lung Function Monitoring; A Randomized Agreement Study

2016

Objective: To determine the agreement between devices and repeatability within devices of the forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory flow at 50% of FVC (FEF50) values measured using the four spirometers included in the study. Methods: 50 (24 women) participants (20-64 years of age) completed maximum forced expiratory flow manoeuvres and measurements were performed using the following devices: MasterScreen, SensorMedics, Oxycon Pro and SpiroUSB. The order of the instruments tested was randomized and blinded for both the participants and the technicians. Re-testing was conducted on a following day within 72 hours …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVital capacitySpirometersTestingArticleMean difference03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineInternal medicinemedicineAdultsRepeatability030212 general & internal medicineLung functionReproducibilitybusiness.industryMeasurementsRepeatabilityrespiratory systemReproducibilityConfidence intervalrespiratory tract diseases030228 respiratory systemPhysical therapyCardiologybusinessThe Open Respiratory Medicine Journal
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct